Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells

Juliane Colditz1,2, Benjamin Rupf1,3, Caroline Maiwald1

  • 1Institute of Human Genetics, Jena University Hospital, Kollegiengasse 10, 07740, Jena, Germany.

Insights

Androgen receptor (AR) signaling influences prostate cancer (PCa) cell behavior. Antiandrogen therapy impacts AR-regulated epithelial-mesenchymal transition (EMT) factors, but only partially counteracts AR activity in castration-resistant PCa (CRPC).

Area of Science:

  • Molecular Oncology
  • Cancer Biology
  • Prostate Cancer Research

Background:

  • Androgen receptor (AR) inhibition is a cornerstone of prostate cancer (PCa) therapy.
  • Prolonged androgen deprivation leads to castration-resistant PCa (CRPC), characterized by metastasis and poor survival.
  • Epithelial-mesenchymal transition (EMT) is implicated in CRPC development and metastasis.

Purpose of the Study:

  • To investigate the role of the AR and the effect of antiandrogen treatment on EMT-related gene expression in PCa cell lines.
  • To examine the impact of androgens and antiandrogens on key EMT factors, including long non-coding RNAs (lncRNAs) like DRAIC.

Main Methods:

  • Utilized androgen-dependent LNCaP and CRPC C4-2 cell lines.
  • Performed short- and long-term treatments with androgens and antiandrogens.
  • Quantified mRNA and protein levels of AR target genes (PSA, FKBP5), EMT markers (E-cadherin, vimentin), EMT transcription factors (Slug, Snail, ZEB1), and DRAIC.

Main Results:

  • Androgens upregulated E-cadherin and vimentin in LNCaP cells, but not in C4-2 cells; antiandrogens had no effect on these markers.
  • Androgen treatment affected mRNA levels of Slug, Snail, ZEB1, and DRAIC in both cell lines; antiandrogens modulated Slug and DRAIC expression.
  • ZEB1 protein levels did not increase despite mRNA upregulation, indicating post-transcriptional regulation; SLUG protein was modulated by androgens and antiandrogens.

Conclusions:

  • Ligand-activated AR regulates several key EMT factors in prostate cancer cells.
  • Antiandrogen therapy partially counteracts AR activity on specific EMT-related genes.
  • Post-transcriptional mechanisms regulate EMT transcription factors, influencing CRPC progression.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K